Poinsettia (300723.SZ): Phase III clinical study of the innovative gout drug AR882 to treat patients with gout with hyperuricemia reached the main end

According to Zhitong Finance App, Yipinhong (300723.SZ) announced that a phase II/III clinical trial of AR882 (generic name: deuteropentinolate) capsules for treating patients with gout with hyperuricemia, led by Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of the company, recently obtained top-line analysis data. Preliminary statistical results showed that AR882 showed positive efficacy and good safety in participants with gout with hyperuricemia. The test results were ideal and achieved the intended goals.

According to reports, AR882 is a Class 1 innovative drug being developed by the company. It is a next-generation highly selective uric acid transport protein (URAT1) inhibitor with global competitiveness. It aims to promote urinary uric acid excretion from the kidneys by inhibiting the reabsorption of uric acid, thereby reducing blood uric acid (SUA) levels, and is used to treat gout and gout stones in patients. AR882 overcomes the shortcomings of resinard and phenbromalone, and can bind to uric acid transporter for a long time to prolong the inhibition period. Clinical results show that its efficacy lasts up to 24 hours. Moreover, blocking the reabsorption of uric acid around the clock does not increase the renal load, can avoid nephrotoxicity, and effectively removes uric acid from the body to achieve the goal of dissolving gout stones.

Currently, through its wholly-owned subsidiary Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd., the company holds 100% of AR882's market interests in the Chinese region (including Hong Kong, Macau, and Taiwan), and has priority ownership to supply AR882 globally to US Arthrosi Therapeutics, Inc. The progress of AR882's domestic phase III clinical trial will not have a significant impact on the company's recent performance.